利用常规血液参数预测侵袭性曲霉病的临床结局
该研究对两项多中心随机试验进行事后二次分析,以GCA研究(n=123)为发现队列、CAS研究(n=251)为验证队列,探索常规血液参数能否预测侵袭性曲霉病治疗反应与12周生存。结果显示血小板动态升高与总生存相关,GMI变化与治疗反应相关,第2周血小板和CRP的ROC分析优于GMI。
要点
- 第2、4周血小板每升高10×10^9/L,12周生存 odds 改善6–18%。
- 第1、2周CRP每下降10 mg/dL,生存 odds 改善13%。
- 基线血小板>30×10^9/L可识别12周生存概率>75%的患者。
核心结论
- 系列血小板升高与总生存相关,而GMI变化趋势与侵袭性曲霉病治疗反应相关。
- 常规简单实验室指标可能有助于侵袭性曲霉病患者的随访反应评估。
研究设计与样本
- 对两项多中心随机试验进行事后二次分析。
- 全球比较曲霉病研究(GCA,n=123)为发现队列,联合抗真菌研究(CAS,n=251)为验证队列。
- 结局指标为治疗反应和12周生存,分析治疗前及治疗期间血小板、半乳甘露聚糖指数(GMI)和C反应蛋白(CRP)水平。
主要发现
- GCA队列和CAS队列的12周生存率分别为70.7%和63.7%。
- GCA队列中,第2周和第4周血小板每升高10×10^9/L,12周生存 odds 改善6–18%(OR 1.06–1.18,95%CI 1.02–1.33)。
- GCA队列中,第1周和第2周CRP每下降10 mg/dL,生存 odds 改善13%(OR 0.87,95%CI 0.78–0.97)。
- CAS队列中,第2周血小板每升高10×10^9/L,12周生存 odds 改善10%(OR 1.10,95%CI 1.04–1.15)。
- 基线时GMI每下降0.1单位,治疗反应 odds 增加3%(OR 0.97,95%CI 0.95–0.99)。
关键数值与推荐
- 第2周血小板、CRP和GMI预测生存的ROC曲线下面积分别为0.76、0.87和0.67。
- 基线血小板计数高于30×10^9/L可明确识别12周生存概率>75%的患者。
临床怎么用
- 随访侵袭性曲霉病患者时,可动态监测血小板和CRP以辅助判断生存预后。
- GMI动态变化可用于辅助评估治疗反应。
局限性
- 本研究为对两项随机试验的事后二次分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In invasive aspergillosis (IA), monitoring response to antifungal treatment is challenging. We aimed to explore if routine blood parameters help to anticipate outcomes following IA. METHODS: Post hoc secondary analysis of two multicenter randomized trials was performed. The Global Comparative Aspergillosis Study (GCA, n = 123) and the Combination Antifungal Study (CAS, n = 251) constituted the discovery and validation cohorts respectively. The outcome measures were response to treatment and survival to 12 weeks. Interval platelet, galactomannan index (GMI) and C-reactive protein (CRP) levels prior and during antifungal treatment were analysed using logistic regression, Kaplan-Meier survival and receiver operating characteristic (ROC) analyses. RESULTS: The 12-week survival was 70.7% and 63.7% for the GCA and CAS cohorts respectively. In the GCA cohort, every 10 × 109/L platelet count increase at week 2 and 4 improved 12-week survival odds by 6-18% (odds ratio (OR) 1.06-1.18, 95% confidence interval (CI) 1.02-1.33). Survival odds also improved 13% with every 10 mg/dL CRP drop at week 1 and 2 (OR 0.87, 95% CI 0.78-0.97). In the CAS cohort, week 2 platelet count was also associated with 12-week survival with 10% improved odds for every 10 × 109/L platelet increase (OR, 1.10, 95% CI 1.04-1.15). A GMI drop of 0.1 unit was additionally found to increase the odds of treatment response by 3% at the baseline of week 0 (OR 0.97, 95% CI 0.95-0.99). Week 2 platelet and CRP levels performed better than GMI on ROC analyses for survival (area under ROC curve 0.76, 0.87 and 0.67 respectively). A baseline platelet count higher than 30 × 109/L clearly identified patients with >75% survival probability. CONCLUSIONS: Higher serial platelets were associated with overall survival while GMI trends were linked to IA treatment response. Routine and simple laboratory indices may aid follow-up of response in IA patients.
引用
- Pang L, Zhao X, Dickens BL, et al. Using routine blood parameters to anticipate clinical outcomes in invasive aspergillosis. Clin Microbiol Infect. 2019. PMID: 31669427. doi:10.1016/j.cmi.2019.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。